Intratumoral Immunotherapy: Is It Ready for Prime Time?-Reference-Cited by-同舟云学术

Intratumoral Immunotherapy: Is It Ready for Prime Time?

Published:2023-05-02 Issue:8 Volume:25 Page:857-867
ISSN:1523-3790
Container-title:Current Oncology Reports
language:en
Short-container-title:Curr Oncol Rep

Author:

Ghosn Mario,Tselikas Lambros^ORCID,Champiat Stéphane,Deschamps Frederic,Bonnet Baptiste,Carre Émilie,Testan Marine,Danlos François-Xavier,Farhane Siham,Susini Sandrine,Suzzoni Steve,Ammari Samy,Marabelle Aurélien,De Baere Thierry

Publisher

Springer Science and Business Media LLC

Subject

Oncology

Link

https://link.springer.com/content/pdf/10.1007/s11912-023-01422-4.pdf

Reference77 articles.

1. Larkin J, Chiarion-Sileni V, Gonzalez R, Grob J-J, Rutkowski P, Lao CD, et al. Five-year survival with combined nivolumab and ipilimumab in advanced melanoma. N Engl J Med. 2019;381:1535–46.

2. Hellmann MD, Paz-Ares L, Bernabe Caro R, Zurawski B, Kim S-W, Carcereny Costa E, et al. Nivolumab plus ipilimumab in advanced non-small-cell lung cancer. N Engl J Med. 2019;381:2020–31.

3. Finn RS, Qin S, Ikeda M, Galle PR, Ducreux M, Kim T-Y, et al. Atezolizumab plus bevacizumab in unresectable hepatocellular carcinoma. N Engl J Med. 2020;382:1894–905.

4. Postow MA, Sidlow R, Hellmann MD. Immune-related adverse events associated with immune checkpoint blockade. N Engl J Med. 2018;378:158–68.

5. Verma V, Sprave T, Haque W, Simone CB, Chang JY, Welsh JW, et al. A systematic review of the cost and cost-effectiveness studies of immune checkpoint inhibitors. J Immunother Cancer. 2018;6:128.

Cited by 8 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Nanofluidic delivery implant sustains localization and maximizes efficacy of intratumoral immunotherapy;Nano Today;2024-06

2. Programable Albumin-Hitchhiking Nanobodies Enhance the Delivery of STING Agonists to Potentiate Cancer Immunotherapy;2024-05-08

3. Controlling the STING pathway to improve immunotherapy;Nature Nanotechnology;2024-03-25

4. Locoregional drug delivery for cancer therapy: Preclinical progress and clinical translation;Journal of Controlled Release;2024-03

5. Characterization of an Injectable Chitosan Hydrogel for the Tunable, Localized Delivery of Immunotherapeutics;ACS Biomaterials Science & Engineering;2024-01-19